enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) major shareholder Growth Opportunities F. Forbion purchased 41,639 shares of the company’s stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $5.97 per share, for a total transaction of $248,584.83. Following the acquisition, the insider now directly owns 2,059,459 shares of the company’s stock, valued at $12,294,970.23. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
enGene Stock Performance
ENGN opened at $9.02 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. The company has a market cap of $398.38 million, a PE ratio of -5.24 and a beta of -0.69. The stock has a 50-day moving average of $6.71 and a 200-day moving average of $9.68. enGene Holdings Inc. has a 52-week low of $4.42 and a 52-week high of $43.00.
enGene (NASDAQ:ENGN – Get Free Report) last announced its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. As a group, equities research analysts forecast that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of brokerages recently issued reports on ENGN. Morgan Stanley restated an “overweight” rating and issued a $40.00 target price on shares of enGene in a report on Wednesday, September 11th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price target on shares of enGene in a research note on Tuesday, September 24th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, enGene presently has an average rating of “Buy” and a consensus target price of $33.67.
Read Our Latest Analysis on ENGN
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Further Reading
- Five stocks we like better than enGene
- What is the NASDAQ Stock Exchange?
- Is Spotify Stock Poised to Soar? Options Traders Think So
- Investing In Preferred Stock vs. Common Stock
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Canadian Penny Stocks: Can They Make You Rich?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.